Cargando…

Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma

Despite aggressive treatment with temozolomide and radiotherapy and extensive research into alternative therapies there has been little improvement in Glioblastoma patient survival. Median survival time remains between 12 and 15 months mainly due to treatment resistance and tumor recurrence. In this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Areeb, Zammam, Stuart, Sarah F., West, Alice J., Gomez, Juliana, Nguyen, Hong P. T., Paradiso, Lucia, Zulkifli, Ahmad, Jones, Jordan, Kaye, Andrew H., Morokoff, Andrew P., Luwor, Rodney B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576591/ https://www.ncbi.nlm.nih.gov/pubmed/33082482 http://dx.doi.org/10.1038/s41598-020-74746-x

Ejemplares similares

The Interleukin-11/IL-11 Receptor Promotes Glioblastoma Survival and Invasion under Glucose-Starved Conditions through Enhanced Glutaminolysis
por: Stuart, Sarah F., et al.
Publicado: (2023)

Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer
por: Zulkifli, Ahmad, et al.
Publicado: (2021)

EGFRvIII Promotes Cell Survival during Endoplasmic Reticulum Stress through a Reticulocalbin 1-Dependent Mechanism
por: Gomez, Juliana, et al.
Publicado: (2021)

Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs
por: Whitehead, Clarissa A., et al.
Publicado: (2018)

Extracellular Vesicles Secreted by Glioma Stem Cells Are Involved in Radiation Resistance and Glioma Progression
por: Ma, Chenkai, et al.
Publicado: (2022)

The role of interleukin-6-STAT3 signalling in glioblastoma
por: West, Alice J., et al.
Publicado: (2018)

The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells
por: Ching, Jared, et al.
Publicado: (2015)

A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker
por: Ma, Chenkai, et al.
Publicado: (2018)

Inhibition of Radiation and Temozolomide-Induced Glioblastoma Invadopodia Activity Using Ion Channel Drugs
por: Dinevska, Marija, et al.
Publicado: (2020)

Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide
por: Vincent, Craig A., et al.
Publicado: (2023)

Temozolomide Treatment Increases Fatty Acid Uptake in Glioblastoma Stem Cells
por: Caragher, Seamus, et al.
Publicado: (2020)

Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
por: She, Lei, et al.
Publicado: (2022)

Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma
por: Gong, Lingli, et al.
Publicado: (2022)

Radiotherapy plus temozolomide in elderly patients with glioblastoma: a “real-life” report
por: Biau, J., et al.
Publicado: (2017)

Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis
por: Buccarelli, Mariachiara, et al.
Publicado: (2018)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma—A Critical Review
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Radiotherapy with or without temozolomide in elderly patients aged ≥ 70 years with glioblastoma
por: Metcalfe, Evrim, et al.
Publicado: (2016)

PCM1 Depletion Inhibits Glioblastoma Cell Ciliogenesis and Increases Cell Death and Sensitivity to Temozolomide()
por: Hoang-Minh, Lan B., et al.
Publicado: (2016)

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines
por: Fishman, Hila, et al.
Publicado: (2023)

Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR
por: Bassi, Rosaria, et al.
Publicado: (2023)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
por: Dunn, J, et al.
Publicado: (2009)

Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings
por: Hilverda, Karen, et al.
Publicado: (2009)

Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional Results
por: Oike, Takahiro, et al.
Publicado: (2013)

Radiotherapy Plus Concurrent or Sequential Temozolomide for Glioblastoma in the Elderly: A Meta-Analysis
por: Yin, An-an, et al.
Publicado: (2013)

Inhibition of O-GlcNAcylation Reduces Cell Viability and Autophagy and Increases Sensitivity to Chemotherapeutic Temozolomide in Glioblastoma
por: Leonel, Amanda V., et al.
Publicado: (2023)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial
por: Compter, Inge, et al.
Publicado: (2020)

Short Interval Infield Sarcoma Development following Resection of Glioblastoma and Adjuvant Radiotherapy and Temozolomide
por: Alotaibi, Fahad E., et al.
Publicado: (2013)

Plasma Levels of microRNA-221 (miR-221) are Increased in Patients with Acute Pulmonary Embolism
por: Liu, Tingwei, et al.
Publicado: (2018)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
por: Herbener, Verena J., et al.
Publicado: (2020)

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: Van Den Bent, Martin, et al.
Publicado: (2020)

Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma
por: William, Doreen, et al.
Publicado: (2018)

OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth()()
por: Towner, Rheal A., et al.
Publicado: (2018)

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation
por: Hou, Zhiwei, et al.
Publicado: (2023)

Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma
por: Cui, Xiaoteng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_np4o2fv2gnoo90t4gvdaobc977